SAL003 140 mg + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Conditions
Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Trial Timeline
Dec 19, 2023 โ Jun 30, 2025
NCT ID
NCT07253584About SAL003 140 mg + Placebo
SAL003 140 mg + Placebo is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT07253584. Target conditions include Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07253584 | Phase 3 | Completed |
| NCT07295418 | Phase 3 | Completed |
Competing Products
5 competing products in Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Evolocumab + Statins (Cardiovascular Agents) | Amgen | Approved | 84 |
| atorvastatin + atorvastatin + atorvastatin | Pfizer | Approved | 84 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |
| SLN360 + Placebo | Medpace | Phase 1 | 30 |
| Bempedoic Acid + Ezetimibe + Placebos | Esperion Therapeutics | Phase 3 | 72 |